101219-39-0

Basic information

• Product Name: ethyl 5-methyl-1-benzothiophene-2-carboxylate
• Synonyms: Ethyl-5-methyl-1-benzothiophen-2-carboxylat
• CAS NO: 101219-39-0
• Molecular Formula: C₁₂H₁₂O₂S
• Molecular Weight: 220.2875
• Mol File: 101219-39-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 336°C at 760 mmHg
• Flash Point: 157°C
• Density: 1.199g/cm³
• Vapor Pressure: 0.000115mmHg at 25°C
• Refractive Index: 1.61
• CAS DataBase Reference: ethyl 5-methyl-1-benzothiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-methyl-1-benzothiophene-2-carboxylate(101219-39-0)
• EPA Substance Registry System: ethyl 5-methyl-1-benzothiophene-2-carboxylate(101219-39-0)

Safety Data

• Hazardous Substances Data: 101219-39-0(Hazardous Substances Data)

Upstream product

• 623-47-2 propynoic acid ethyl ester 
• 5858-28-6 5-methyl-2-nitrobenzaldehyde 
• 623-51-8 ethyl 2-sulfanylacetate 
• 93249-44-6 2-fluoro-5-methylbenzaldehyde 

Downstream Products

• 1505-62-0 5-methyl-benzo[b]thiophene-2-carboxylic acid 

Relevant articles and documents

GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Substituted imidazoles, pharmaceutical compositions containing these, and the use thereof as antagonists of angiotensin II receptors for the treatment of high blood pressure

The invention relates to compounds of the formula I STR1 in which X, Y and Z are identical or different and are N or CR 2, R 1 and R 2 are as defined in the description, L is an alkylene radical, q is 0 or 1, and A is the radical of a fused heterobicyclic compound. The invention furthermore relates to a process for preparing the said compounds, agents containing these, and the use thereof in the treatment of high blood pressure.